Clinical Trial Update: A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]

View source ↗

Summary

The document reports the completion and posting of results for a Phase 1/2 study evaluating ASP7517 for safety, tolerability, and preliminary efficacy in relaps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• ASP7517

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-06-25